NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Cytokinetics, Incorporated (CYTK) Stock Analysis

Cytokinetics, Incorporated (CYTK) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

CYTK

$62.86

−$1.09 (−1.70%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare CYTK with… →

CYTK Key Statistics

As of Oct 21, 2026
Trading
Open
$64.30
Previous Close
$63.95
Day's Range
62.46–64.78
52-Week Range
54.30–88.31
Volume
1.08M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.41
Valuation
Market Cap
$8.74B
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
129.14
EPS (ttm)Profit attributable to each share over the last twelve months.
−7.22
Financials (FY)
Revenue (FY)
$88.04M+376.56%
Net Income (FY)
−$784.96M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
139.02M
1-Year Return
+8.79%
Dividend and dates
Earnings Date
November 4, 2026
Avg Volume
1.97M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, CYTK closed at $62.86, +8.79% over 1 year.

Cytokinetics, Incorporated (CYTK) has a market capitalization of $8.74B.

In fiscal 2025, CYTK reported revenue of $88.04M.

CYTK Stock Return by Calendar Year

Cytokinetics, Incorporated (CYTK) 10-year return: what $10,000 became

1 year
$10,000 $10,879
+8.79%
5 years
$10,000 $17,360
+73.60%
10 years
$10,000 $68,400
+584.00%

If you had invested $10,000 in Cytokinetics, Incorporated (CYTK) 10 years ago, at the close on October 21, 2016, it would have been worth $68,400 at the close on October 21, 2026: +584.00% in total, +21.20% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−1.07%
2025+35.08%
2024−43.66%
2023+82.21%
2022+0.53%
2021+119.35%
2020+95.85%
2019+67.88%
2018−22.45%
2017−32.92%
2016 (partial year)+1.25%

As of October 21, 2026.

CYTK Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$88.04M−$784.96M−891.6%
2024$18.47M−$589.53M−3,191.1%
2023$7.53M−$526.24M−6,988.6%
2022$94.59M−$388.96M−411.2%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$88.04M−$327.99M−$612.26M−$784.96M−891.6%
2024$18.47M−$320.93M−$536.25M−$589.53M−3,191.1%
2023$7.53M−$322.59M−$496.21M−$526.24M−6,988.6%
2022$94.59M−$146.23M−$324.20M−$388.96M−411.2%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

CYTK Valuation vs Biotechnology Median

Median of 608 stocks
MetricCYTKBiotechnology medianvs median
P/S ratio129.1413.309.7x the median

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Cytokinetics, Incorporated (CYTK) carries a market capitalisation of $8.74B. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 673.

CYTK last closed at $62.86 on October 21, 2026. That is −$1.09 (−1.70%) against the previous close. Over the past 52 weeks the price has ranged from $54.30 to $88.31. The latest close sits 15.76% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $88.04M. Against the prior fiscal year total of $18.47M, that is a change of +376.56%. The same year closed with a net loss of $784.96M. Trailing earnings per share are −7.22.

Across the 4 fiscal years on file, revenue moves from $94.59M in 2022 to $88.04M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. Measured against sales, the shares trade at 129.14 times revenue. On price-to-sales that is 9.7 times the Biotechnology median of 13.3. The medians here are taken across 608 Biotechnology companies that report the metric.

Over the trailing twelve months the total return is +8.79%. Across 10 years the annualized return works out at +21.20%. Beta against the wider market is reported at 0.41. Daily returns over the trailing 10 years annualize to a volatility of 67.87%.

Growth & Income

The record shows no dividend for CYTK.

The strongest complete calendar year on file is 2021 at +119.35%; the weakest is 2024 at −43.66%. Of the 9 complete calendar years on file, 6 finished higher. 2026 is still running; the total return is −1.07% year to date.

Peer Comparison

Cytokinetics, Incorporated (CYTK) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Cytokinetics, Incorporated CYTK $8.74B —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Cytokinetics, Incorporated has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Cytokinetics, Incorporated

Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.

Visit website →